Conditions
- Acquired:
- antiphospholipid syndrome,
including:
- catastrophic antiphospholipid syndrome
- autoimmune disease
- hormone-related thrombosis
- malignancy
- Arterial thromboembolism
- Sequelae of venous / arterial
thromboembolism
- Thrombophilias:
- congenital, such as protein
C / S deficiencies
- Venous thromboembolic disease:
For each presentation and condition, Advanced Trainees will know how to:
Synthesise
- recognise the clinical presentation
- identify relevant epidemiology, prevalence, pathophysiology, and clinical science
- take a comprehensive clinical history
- conduct an appropriate examination
- establish a differential diagnosis
- plan and arrange appropriate investigations
- consider the impact of illness and disease on patients and their quality of life when developing a management plan
Manage
- provide evidence-based management
- prescribe therapies tailored to patients’ needs and conditions
- recognise potential complications of disease and its management, and initiate preventative strategies
- involve multidisciplinary teams
Consider other factors
- identify individual and social factors and the impact of these on diagnosis and management
Presentations
- Thrombocytopenia
- Thromboembolic disease, including
rare sites of thrombosis, such as:
- cerebral venous sinus
thrombosis
- mesenteric / portal / splanchnic
vein thrombosis
Conditions
- JAK2V617F-positive
myeloproliferative neoplasms
- Paroxysmal nocturnal
haemoglobinuria
- PF4-immune disorders, including
heparin-induced thrombocytopenia
(HIT), including:
- laboratory testing
- management
- other PF4-immune disorders:
- autoimmune HIT
- spontaneous HIT
- vaccine-induced thrombotic
thrombocytopenia
- presentation
For each presentation and condition, Advanced Trainees will know how to:
Synthesise
- recognise the clinical presentation
- identify relevant epidemiology, prevalence, pathophysiology, and clinical science
- take a comprehensive clinical history
- conduct an appropriate examination
- establish a differential diagnosis
- plan and arrange appropriate investigations
- consider the impact of illness and disease on patients and their quality of life when developing a management plan
Manage
- provide evidence-based management
- prescribe therapies tailored to patients’ needs and conditions
- recognise potential complications of disease and its management, and initiate preventative strategies
- involve multidisciplinary teams
Consider other factors
- identify individual and social factors and the impact of these on diagnosis and management
- Anticoagulant medications:
- appropriate choice of agent
- dosing
- duration of therapy
- mechanism of action
- monitoring
- reversal
- Complications, diagnostic strategies, natural history, and presentation
of inherited and acquired thrombophilia
- Inherited and acquired risk factors and associations in patients with
thromboembolic disease
- Pathophysiology of arterial and venous thrombosis, including
epidemiology and molecular basis of thrombophilia
- Techniques for the measurement of recognised laboratory
thrombophilia
- Anticoagulant levels
- Antiphospholipid antibody tests
- Basis of lupus anticoagulant assays, and interpreting their clinical
impact
- Imaging modalities used in diagnosis and follow-up of thromboembolic
disease
- Thrombophilia screening and its limited indications
Anti-thrombotic therapy
- Follow-up of patients receiving anticoagulants, and management
of bleeding
- Perioperative management of patients receiving antithrombotic
therapy, and the role of reversal agents (as locally available)
- Risks and benefits of antithrombotic therapy, including potential
adverse effects
Pregnancy
- Changes to haemostasis
- Diagnostic strategies used for thrombosis in pregnancy
- Management of thrombosis in pregnancy, and prophylaxis in
subsequent pregnancies
Transgender health
- Awareness of transgender health care needs, and recognition
of the psychosocial aspects impacting haematology outcomes
- Consideration of conditions, such as:
- polycythaemia in transgender men on testosterone therapy
- potential impact on thrombotic risk in transgender women taking
oestrogen
- Consideration of hormonal treatments, including gender-affirming
hormone therapy (GAHT), and its impact on haematological parameters
such as haematocrit, haemoglobin, and thrombotic risk
